Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer
Status:
Completed
Trial end date:
2017-07-20
Target enrollment:
Participant gender:
Summary
The purpose of the study is to see if the drug KU 0059436 is effective and well tolerated in
treating patients with measurable BRCA1- or BRCA2-positive advanced ovarian cancer and for
whom no curative therapeutic option exists.